While their role in OSCC is not as well-defined as in breast and ovarian cancers, emerging evidence suggests that BRCA1 and BRCA2 contribute to tumor initiation, progression, and therapeutic resistance (25–27, 53, 75). Here, BRCA1 is linked to neoplasm.